Form 4: Intra-Cellular Therapies Director Riggs Rory B Reports Disposal of Shares and Options Following Merger with Johnson & Johnson

Director Riggs Rory B reports the disposal of common stock and stock options in Intra-Cellular Therapies following the company's merger with Johnson & Johnson on April 2, 2025.

Summary

• On April 2, 2025, Riggs Rory B, a director of Intra-Cellular Therapies, reported the disposal of common stock and stock options due to the merger with Johnson & Johnson.
• The merger, effective April 2, 2025, involved Fleming Merger Sub, Inc. merging with Intra-Cellular Therapies, with the latter surviving as a wholly-owned subsidiary of Johnson & Johnson.
• Each share of Intra-Cellular Therapies common stock was converted into the right to receive $132.00 in cash.
• Outstanding stock options with an exercise price less than $132.00 were canceled and converted into the right to receive cash equal to the difference between $132.00 and the exercise price, multiplied by the number of shares underlying the option.
• Options with an exercise price equal to or exceeding $132.00 were canceled for no consideration.
• Restricted stock units (RSUs) were canceled and converted into the right to receive cash equal to $132.00 per share, with RSUs granted in 2025 payable at the original vesting date, subject to accelerated vesting in certain circumstances.
• Riggs Rory B disposed of 131,512 shares of common stock at $132 per share.
• Various stock options to purchase common stock at prices ranging from $12.45 to $67.77 were disposed of.
• 2,951 restricted stock units were also disposed of.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a clear exit strategy for shareholders at a defined price. The value of the deal is dependent on the premium paid above the previous share price.

Positives

• Shareholders received $132.00 per share in cash as a result of the merger.
• Option holders with in-the-money options received cash for the difference between the merger consideration and the exercise price.

Negatives

• Option holders with options at or above the merger consideration received no compensation for their options.
• The company is now a wholly-owned subsidiary of Johnson & Johnson, meaning it is no longer publicly traded.

Future Outlook

The company will operate as a wholly-owned subsidiary of Johnson & Johnson.

Industry Context

This announcement reflects ongoing consolidation within the pharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates or technologies.

Comparison to Industry Standards

• Merger and acquisition (M&A) transactions in the pharmaceutical industry often involve a premium paid to the target company's shareholders.
• The $132 per share consideration should be compared to the trading price of Intra-Cellular Therapies prior to the announcement of the merger to assess the premium received by shareholders.
• Comparable transactions include the acquisition of Alexion Pharmaceuticals by AstraZeneca and the acquisition of Biohaven Pharmaceutical by Pfizer, which also involved significant premiums.

Stakeholder Impact

• Shareholders received cash for their shares.
• Employees may experience changes as the company integrates into Johnson & Johnson.
• Customers will likely see continued access to Intra-Cellular Therapies' products under Johnson & Johnson's ownership.

Key Dates

Keywords

Merger, Intra-Cellular Therapies, Johnson & Johnson, Form 4, Director, Stock Options, Common Stock, RSUs, Disposal, Securities